Cambridge Healthtech Institute's Second Annual
( 微生物表现 )
Optimizing the Expression and Production of Microbial Expressed Proteins
2018年1月11日 - 12日 | Hilton San Diego Bayfront | San Diego, CA
Microbial expression systems offer significant advantages over other hosts by providing faster development times, greater yields, lower production costs, particularly in E. coli which is one of the most widely used hosts for protein production. However, limitations around glycosylation and central metabolic pathways poses significant challenges.
Cambridge Healthtech Institute's Microbial Production conference covers the latest developments in microbial expression and production - from host strain development to metabolic engineering, assembly to scale-up, downstream processing to potential aggregation - with particular focus on the role of E. coli for biotherapeutics, novel products and other industrial applications.
Opportunities and Challenges in Microbial-Based Expression
Pfizer E. coli Expression Platform Part I: Development and Testing of an Integrated Cloning and Expression System
Kevin Rust, Ph.D., Principal Scientist, Bioprocess R&D, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc.
Pfizer E. coli Expression Platform Part II: Application of the Platform to Test Reliably and Rapidly Achieve Increased Protein Yields
Marie Caparon, Ph.D., Associate Research Fellow, Bioprocess R&D, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc.
Membrane Protein Expression in Pichia pastoris Using Autoinduction
Jonas Lee, Ph.D., Scientist, Amgen
E. coli Periplasmic Expression of Antibody Fab' Fragments
Mark Ellis, Principal Scientist, Protein Expression and Purification, UCB Pharma
Presentation to be Announced
Matthew P. DeLisa, Ph.D., William L. Lewis Professor of Engineering, Chemical and Biomolecular Engineering, Cornell University
Microbial Host Engineering, Strain Development and BioProcessing
High Throughput Screening for Refolding Conditions of Bacterially Produced Proteins
Kenneth Walker, Ph.D., Director of Research, Biologics, Amgen
Tackling Development Challenges of Non-MAb Biotherapeutics in Microbial Systems using HTPD
Georg Klima, Dipl. Ing., Executive Director, Process Science, Boehringer Ingelheim RCV GmbH & Co KG
A S. cerevisiae Process Characterization for Production of a Therapeutic Recombinant Protein Using a Multivariate Analysis
Juan Aon, Ph.D., Senior Manager, MCCD, RD Biopharm, R&D, GSK
Microbial Expression and Production of Pasylated Proteins and Peptides: Biobetters with Extended Half-Life and Enhanced Action
Uli Binde, Ph.D., CTO, XL-Protein
Sebastian Schuck, Ph.D., Head, Business Development, Wacker Biotech GmbH
Recoded E. coli for Incorporation of Non-Natural Amino Acids and Also for the Purpose of Genetic Isolation
Farren Isaacs, Ph.D., Assistant Professor, Molecular Cellular and Development Biology, Yale University
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines
Christian Harding, Ph.D., CSO, VaxNewMo
A Strategy for Production of Correctly Folded Disulfide-Rich Peptides in the Periplasm of E. coli
Natalie Saez, Ph.D., Research Officer, Institute for Molecular Bioscience, The University of Queensland